Literature DB >> 24416081

LC-MS/MS quantification of salvinorin A from biological fluids.

Michael J Caspers1, Todd D Williams1, Kimberly M Lovell1, Anthony Lozama2, Eduardo R Butelman3, Mary Jeanne Kreek3, Matthew Johnson4, Roland Griffiths4, Katherine Maclean4, Thomas E Prisinzano1.   

Abstract

A facile method for quantifying the concentration of the powerful and widely available hallucinogen salvinorin A (a selective kappa opioid agonist) from non-human primate cerebrospinal fluid (CSF) and human plasma has been developed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in positive electrospray ionization (ESI) mode. With CSF solid phase extraction can be avoided completely by simply diluting each sample to 10 % (v/v) acetonitrile, 1 % (v/v) formic acid and injecting under high aqueous conditions for analyte focusing. Extensive plasma sample preparation was investigated including protein precipitation, SPE column selection, and plasma particulate removal. Human plasma samples were centrifuged at 21,000 × gravity for 4 minutes to obtain clear particulate-free plasma, from which 300 μl was spiked with internal standard and loaded onto a C18 SPE column with a 100 mg mL-1 loading capacity. Guard columns (C18, hand packed 1 mm × 20 mm) were exchanged after backpressure increased above 4600psi, about 250 injections. A shallow acetonitrile/water gradient was used, 29 to 33% CH3CN over 8 minutes to elute salvinorin A. Reduction of chemical noise was achieved using tandem mass spectrometry with multiple reaction monitoring while sensitivity increases were observed using a 50 μL injection volume onto a small bore analytical column (C18, 1 mm ID × 50 mm) thus increasing peak concentration. Limits of quantification were found to be 0.0125 ng mL-1 (CSF) and 0.05 ng mL-1 (plasma) with interday precision and accuracy below 1.7 % and 9.42 % (CSF) and 3.47 % and 12.37 % (plasma) respectively. This method was used to determine the concentration of salvinorin A from an in vivo Rhesus monkey study and a trial of healthy human research participants, using behaviorally active doses.

Entities:  

Year:  2013        PMID: 24416081      PMCID: PMC3885280          DOI: 10.1039/C3AY40810H

Source DB:  PubMed          Journal:  Anal Methods        ISSN: 1759-9660            Impact factor:   2.896


  20 in total

1.  Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.

Authors:  Eduardo R Butelman; Michael Caspers; Kimberly M Lovell; Mary Jeanne Kreek; Thomas E Prisinzano
Journal:  J Pharmacol Exp Ther       Date:  2012-03-20       Impact factor: 4.030

2.  Dopamine D(2) receptor function is compromised in the brain of the methionine sulfoxide reductase A knockout mouse.

Authors:  Derek B Oien; Andrea N Ortiz; Alexander G Rittel; Rick T Dobrowsky; Michael A Johnson; Beth Levant; Stephen C Fowler; Jackob Moskovitz
Journal:  J Neurochem       Date:  2010-03-31       Impact factor: 5.372

3.  The detection and quantitative analysis of the psychoactive component of Salvia divinorum, salvinorin A, in human biological fluids using liquid chromatography-mass spectrometry.

Authors:  Pamela C McDonough; Justin M Holler; Shawn P Vorce; Thomas Z Bosy; Joseph Magluilo; Marilyn R Past
Journal:  J Anal Toxicol       Date:  2008 Jul-Aug       Impact factor: 3.367

4.  Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence.

Authors:  Jacob M Hooker; Thomas A Munro; Cécile Béguin; David Alexoff; Colleen Shea; Youwen Xu; Bruce M Cohen
Journal:  Neuropharmacology       Date:  2009-07-08       Impact factor: 5.250

5.  Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates.

Authors:  Matthew D Schmidt; Mark S Schmidt; Eduardo R Butelman; Wayne W Harding; Kevin Tidgewell; Daryl J Murry; Mary Jeanne Kreek; Thomas E Prisinzano
Journal:  Synapse       Date:  2005-12-01       Impact factor: 2.562

6.  Impaired dopamine release and uptake in R6/1 Huntington's disease model mice.

Authors:  Andrea N Ortiz; Benjamin J Kurth; Gregory L Osterhaus; Michael A Johnson
Journal:  Neurosci Lett       Date:  2011-01-20       Impact factor: 3.046

7.  The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects.

Authors:  Eduardo R Butelman; Szymon Rus; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2010-01-19       Impact factor: 4.530

8.  Salvinorins D-F, new neoclerodane diterpenoids from Salvia divinorum, and an improved method for the isolation of salvinorin A.

Authors:  Thomas A Munro; Mark A Rizzacasa
Journal:  J Nat Prod       Date:  2003-05       Impact factor: 4.050

Review 9.  Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A.

Authors:  L J Valdés
Journal:  J Psychoactive Drugs       Date:  1994 Jul-Sep

10.  The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.

Authors:  Eduardo R Butelman; Todd J Harris; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2003-10-30       Impact factor: 4.530

View more
  2 in total

1.  Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans.

Authors:  Matthew W Johnson; Katherine A MacLean; Michael J Caspers; Thomas E Prisinzano; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-02-15       Impact factor: 4.153

Review 2.  Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects.

Authors:  Andreia Machado Brito-da-Costa; Diana Dias-da-Silva; Nelson G M Gomes; Ricardo Jorge Dinis-Oliveira; Áurea Madureira-Carvalho
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.